Lunit obtains new CE mark for AI DBT answer
South Korean medical AI firm Lunit has acquired a CE mark below Europe’s newest Medical Machine Regulation for its AI software program for digital breast tomosynthesis (DBT) evaluation.
Known as Lunit INSIGHT DBT, the software program answer analyses 3D pictures from DBT, enabling quick and correct analysis of breast most cancers.
In a press assertion, Lunit disclosed its plan to begin rolling out the software program product in Europe by the top of March, noting an uptick in curiosity. It additionally introduced its plan to start the method of buying the US FDA’s approval for Lunit INSIGHT DBT within the third quarter. The expertise has already been authorised for commercialisation in South Korea early this yr.
Jolly Good creates emergency care VR content material with Brigham and Ladies’s Hospital
Jolly Good has revealed its newest collaboration with Harvard Medical College-affiliated Brigham and Ladies’s Hospital (BWH).
In response to a press assertion, their partnership seeks to confirm the tutorial advantages of medical VR and its implementation in North America.
As a part of their collaboration, the organisations have developed VR content material on emergency care.
In the meantime, the Japanese VR firm introduced that Dr Kei Ouchi, affiliate professor at Harvard Medical College, has change into its medical advisor who will information its full entry into the US medical market.
IIT Madras researchers develop coronavirus antibodies database
Researchers from the Indian Institute of Know-how Madras (IIT Madras) have constructed an open-source database of coronaviruses’ antibodies.
Known as Ab-CoV, the net database contains antibody options equivalent to binding affinity and neutralisation profiles, supply, and figuring out viral proteins and strains. At present, Ab-CoV has information on 1,780 coronavirus-related antibodies and incorporates greater than 3,200 information factors on their options.
“Ab-CoV is an exhaustive repository of antibodies, not simply particular to SARS-CoV-2, but in addition to different members of the coronavirus household, equivalent to SARS and MERS viruses,” Dr Vani Janakirama of the Division of Biotechnology defined.
Based mostly on a press assertion, the Ab-CoV database can be utilized to assist the event of recent medication towards rising variants of SARS-CoV-2, the virus which causes COVID-19.
“This repository would assist in comparative research amongst totally different neutralising antibodies throughout coronaviruses and assess their properties and interplay patterns with epitopes on the native and mutant viral proteins. Such an effort ultimately would assist to gauge the efficacy of those antibodies in direction of present and rising viral variants,” Dr Janakirama added.